Literature DB >> 26530794

Standardization, Evaluation, and Area-Under-Curve Analysis of Human and Murine Treg Suppressive Function.

Tatiana Akimova1, Matthew H Levine2, Ulf H Beier3, Wayne W Hancock4.   

Abstract

FOXP3+ T-regulatory (Treg) cells have important roles in immune homeostasis, and alterations in their number and function can predispose to diseases ranging from autoimmunity to allograft rejection and tumor growth. Reliable identification of human Tregs remains a persistent problem due to a lack of specific markers. The most definitive Treg characterization currently involves combined assessment of phenotypic, epigenetic and functional parameters, with the latter typically involving in vitro Treg suppression assays. Unfortunately, suppression assays are frequently performed using differing methods and readouts, limiting comparisons between studies. We provide a perspective on our experience with human and murine Treg suppression assay conditions, including Treg data obtained in clinical transplant studies, Tregs isolated from healthy donors and treated with epigenetically active compounds, and Tregs from standard murine strains (C57BL/6 and BALB/c). We provide detailed descriptions and illustrations of typical problems, shortcomings and troubleshooting; describe new modifications and approaches; and present a new method for calculation of suppressive assay data using a modified area-under-curve (AUC) method. This method allows us to directly compare Treg suppressive function between multiple patients (such as in clinical transplant studies), to reliably track changes in Treg function from the same person over time, or compare effects of Treg-modulating compounds tested with different healthy donors Tregs in separate or combined experimental settings.

Entities:  

Keywords:  FOXP3+ regulatory T cells; Suppression assay; Tregs

Mesh:

Substances:

Year:  2016        PMID: 26530794      PMCID: PMC5554116          DOI: 10.1007/978-1-4939-3139-2_4

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  30 in total

Review 1.  In vitro assays for immune monitoring in transplantation.

Authors:  Maria P Hernandez-Fuentes; Alan Salama
Journal:  Methods Mol Biol       Date:  2006

2.  Assessment of suppressive capacity by human regulatory T cells using a reproducible, bi-directional CFSE-based in vitro assay.

Authors:  Anya Schneider; Jane H Buckner
Journal:  Methods Mol Biol       Date:  2011

Review 3.  The importance of the indirect pathway of allorecognition in clinical transplantation.

Authors:  M Refik Gökmen; Giovanna Lombardi; Robert I Lechler
Journal:  Curr Opin Immunol       Date:  2008-08-04       Impact factor: 7.486

4.  Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs.

Authors:  Tatiana Akimova; Guanghui Ge; Tatiana Golovina; Tatiana Mikheeva; Liqing Wang; James L Riley; Wayne W Hancock
Journal:  Clin Immunol       Date:  2010-05-15       Impact factor: 3.969

Review 5.  Control of inflammation by integration of environmental cues by regulatory T cells.

Authors:  Ashutosh Chaudhry; Alexander Y Rudensky
Journal:  J Clin Invest       Date:  2013-03-01       Impact factor: 14.808

6.  Human regulatory T cells rapidly suppress T cell receptor-induced Ca(2+), NF-κB, and NFAT signaling in conventional T cells.

Authors:  Angelika Schmidt; Nina Oberle; Eva-Maria Weiss; Diana Vobis; Stefan Frischbutter; Ria Baumgrass; Christine S Falk; Mathias Haag; Britta Brügger; Hongying Lin; Georg W Mayr; Peter Reichardt; Matthias Gunzer; Elisabeth Suri-Payer; Peter H Krammer
Journal:  Sci Signal       Date:  2011-12-20       Impact factor: 8.192

7.  An optimized CFSE-based T-cell suppression assay to evaluate the suppressive capacity of regulatory T-cells induced by human tolerogenic dendritic cells.

Authors:  M A Boks; J J Zwaginga; S M van Ham; A ten Brinke
Journal:  Scand J Immunol       Date:  2010-08       Impact factor: 3.487

8.  Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces.

Authors:  Yuri P Rubtsov; Jeffrey P Rasmussen; Emil Y Chi; Jason Fontenot; Luca Castelli; Xin Ye; Piper Treuting; Lisa Siewe; Axel Roers; William R Henderson; Werner Muller; Alexander Y Rudensky
Journal:  Immunity       Date:  2008-04       Impact factor: 31.745

9.  Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state.

Authors:  T Takahashi; Y Kuniyasu; M Toda; N Sakaguchi; M Itoh; M Iwata; J Shimizu; S Sakaguchi
Journal:  Int Immunol       Date:  1998-12       Impact factor: 4.823

10.  CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production.

Authors:  A M Thornton; E M Shevach
Journal:  J Exp Med       Date:  1998-07-20       Impact factor: 14.307

View more
  21 in total

Review 1.  FOXP3+ Treg as a therapeutic target for promoting anti-tumor immunity.

Authors:  Theresa L Whiteside
Journal:  Expert Opin Ther Targets       Date:  2018-04-10       Impact factor: 6.902

2.  Targeting Sirtuin-1 prolongs murine renal allograft survival and function.

Authors:  Matthew H Levine; Zhonglin Wang; Haiyan Xiao; Jing Jiao; Liqing Wang; Tricia R Bhatti; Wayne W Hancock; Ulf H Beier
Journal:  Kidney Int       Date:  2016-03-16       Impact factor: 10.612

3.  Human lung tumor FOXP3+ Tregs upregulate four "Treg-locking" transcription factors.

Authors:  Tatiana Akimova; Tianyi Zhang; Dmitri Negorev; Sunil Singhal; Jason Stadanlick; Abhishek Rao; Michael Annunziata; Matthew H Levine; Ulf H Beier; Joshua M Diamond; Jason D Christie; Steven M Albelda; Evgeniy B Eruslanov; Wayne W Hancock
Journal:  JCI Insight       Date:  2017-08-17

4.  Inhibiting the coregulator CoREST impairs Foxp3+ Treg function and promotes antitumor immunity.

Authors:  Yan Xiong; Liqing Wang; Eros Di Giorgio; Tatiana Akimova; Ulf H Beier; Rongxiang Han; Matteo Trevisanut; Jay H Kalin; Philip A Cole; Wayne W Hancock
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

5.  How little is known about the role of human FOXP3+ Tregs in tumors.

Authors:  Tatiana Akimova; Wayne W Hancock
Journal:  Expert Opin Ther Targets       Date:  2018-07-19       Impact factor: 6.902

6.  Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments.

Authors:  Alessia Angelin; Luis Gil-de-Gómez; Satinder Dahiya; Jing Jiao; Lili Guo; Matthew H Levine; Zhonglin Wang; William J Quinn; Piotr K Kopinski; Liqing Wang; Tatiana Akimova; Yujie Liu; Tricia R Bhatti; Rongxiang Han; Benjamin L Laskin; Joseph A Baur; Ian A Blair; Douglas C Wallace; Wayne W Hancock; Ulf H Beier
Journal:  Cell Metab       Date:  2017-04-13       Impact factor: 27.287

7.  T Cell-Specific Adaptor Protein Regulates Mitochondrial Function and CD4+ T Regulatory Cell Activity In Vivo following Transplantation.

Authors:  Johannes Wedel; Maria P Stack; Tatsuichiro Seto; Matthew M Sheehan; Evelyn A Flynn; Isaac E Stillman; Sek Won Kong; Kaifeng Liu; David M Briscoe
Journal:  J Immunol       Date:  2019-09-20       Impact factor: 5.422

Review 8.  Histone/protein deacetylase inhibitor therapy for enhancement of Foxp3+ T-regulatory cell function posttransplantation.

Authors:  L Wang; U H Beier; T Akimova; S Dahiya; R Han; A Samanta; M H Levine; W W Hancock
Journal:  Am J Transplant       Date:  2018-04-21       Impact factor: 8.086

9.  HDAC5 controls the functions of Foxp3(+) T-regulatory and CD8(+) T cells.

Authors:  Haiyan Xiao; Jing Jiao; Liqing Wang; Shaun O'Brien; Kheng Newick; Liang-Chuan S Wang; Eva Falkensammer; Yujie Liu; Rongxiang Han; Veena Kapoor; Finn K Hansen; Thomas Kurz; Wayne W Hancock; Ulf H Beier
Journal:  Int J Cancer       Date:  2016-01-19       Impact factor: 7.396

10.  Loss of HDAC6 alters gut microbiota and worsens obesity.

Authors:  Arnon D Lieber; Ulf H Beier; Haiyan Xiao; Benjamin J Wilkins; Jing Jiao; Xinmin S Li; Rebecca C Schugar; Christopher M Strauch; Zeneng Wang; J Mark Brown; Stanley L Hazen; Nicholas A Bokulich; Kelly V Ruggles; Tatiana Akimova; Wayne W Hancock; Martin J Blaser
Journal:  FASEB J       Date:  2018-08-13       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.